Navigation Links
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Date:7/25/2012

NATICK, Mass., July 25, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330. KPT-330 is the first oral SINE CRM1 antagonist to enter human studies.  SINEs specifically and irreversibly inhibit the nuclear export protein CRM1 (chromosome region maintenance protein 1), also called exportin 1 (XPO1).  CRM1 is the exclusive mediator of nuclear export of p53, p73, pRb, FOXO, p21, p27, BRACA1, the endogenous inhibitor of Nuclear Factor kB (NF-kB) known as IkB, and other tumor suppressor and growth regulatory proteins. Nuclear export of these key proteins leads to their functional inactivation.  Blockade of CRM1 leads to accumulation and activation of tumor suppressor and growth regulatory proteins in the nucleus, leading to potent and selective tumor cell apoptosis while sparing normal cells. 

(Logo:  http://photos.prnewswire.com/prnh/20120508/NE02031LOGO )

Patient dosing has been initiated in two phase 1 studies.  The primary endpoints of both studies are to determine the safety and tolerability profile and the maximum tolerated dose of KPT-330 given orally 2-3 times per week. The first study includes patients with advanced solid tumors whose disease has progressed after at least one prior therapy for metastatic disease (NCT01607905).  The second study includes patients with advanced hematologic malignancies including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and Waldenstrom's macroglobulinemia whose disease has relapsed after standard therapies (NCT01607892). Sharon Shacham, PhD, MBA, Karyopharm's Founder, Chief Scientific Officer, and head of research and development commented, "The initiation of these two Phase 1 trials with KPT-330 is a key milestone since the closing of our Series
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. PTC Therapeutics Closes $30 Million Financing
3. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
4. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
5. Echo Therapeutics Expands License Agreement with Ferndale Pharma
6. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
7. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
8. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
9. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
10. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... FRANKFURT , Deutschland, 4. März 2015 ... führender Anbieter von medizinischen Bildmanagementlösungen für Unternehmen, ... Ernennung von Randolph Sternberg zum Director of ... Director of Operations weiter aus. ... Randolph Sternberg ist für den ...
(Date:3/4/2015)... , March 4, 2015  ECR Booth #317/Expo C ... is showcasing a full spectrum of X-ray imaging solutions ... reduce costs, and enable greater patient throughput for manufacturers ... systems.  These solutions are on display at the Annual ... Vienna, Austria this week.   ...
(Date:3/4/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming 27 th Annual ROTH Conference, taking place ...  Dr. Michael Berelowitz , Chairman of ... corporate overview on March 10, 2015.   ...
Breaking Medicine Technology:TeraRecon baut seine Präsenz in EMEA aus 2TeraRecon baut seine Präsenz in EMEA aus 3Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3
... 2012 Ranbaxy Laboratories Inc. (RLI), a wholly owned ... that the U.S. Food and Drug Administration (FDA) has ... acne medication isotretinoin, for the treatment of severe recalcitrant ... firm, Cipher Pharmaceuticals Inc., RLI is expected to launch ...
... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... it has received approval for a key patent by ... and Compositions for Oral Administration of Exenatide," covers oral ... now consists of three issued patents and 34 patents ...
Cached Medicine Technology:Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA 2Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand 2Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand 3
(Date:3/4/2015)... March 04, 2015 Alliance Healthcare Foundation ... wellness for those in need in San Diego and ... organizations through its Mission Support Grants program with awards ... organizations applied for AHF’s Mission Support Grants program. Grant ... board of trustees and program committee, as well as ...
(Date:3/4/2015)... State officials have awarded $82,500 to ... Public Health at Georgia State University, to support the ... Georgia’s Division of Family and Children Services (DFCS) as ... Center. , The 1-800-CHILDREN Helpline is a top ... referral services that promote the wellbeing of children while ...
(Date:3/4/2015)... Estates, CA (PRWEB) March 04, 2015 ... clever dialogue and lyrical music, will be performed by ... Rolling Hills Estates, CA, this March 6-22, 2015, on ... Arts Center at Peninsula High School (27118 Silver ... available one hour before the program or may be ...
(Date:3/4/2015)... March 04, 2015 The report ... client survey, marketing channels, industry development trend and ... the industry, including spices definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is ... joined the company as Chief Technology Officer. Mr. Dvorak ... the company, including customer-centric strategies and initiatives, and promoting ... experience as a technology executive and visionary. Prior to ... FBI including oversight of enterprise data management, analytic software ...
Breaking Medicine News(10 mins):Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3
... active antiretroviral treatment (HAART) needs to be careful// ... Belgium. ,Highly active antiretroviral treatment can dramatically ... expectancy. This is especially helpful for patients with ... to have a full commitment to the antiviral ...
... neck cancer who are undergoing radiation// therapy can now ... ,Oropharyngeal candidiasis is a fungal infection in the ... also called thrush. The symptoms of the disease are ... when removed leaves a bleeding surface. This is a ...
... often had complained of a sudden increase in weight, especially ... this sudden influx of weight often results in obesity that ... rise in type 2 diabetes cases, cardiovascular diseases and other ... may be due to a drop in the estrogen levels ...
... had affected a total of 423 cases in Angola,// which ... the form of a vaccine. ,A virus causes Marburg ... Ebola hemorrhagic fever. The disease is a rare condition but ... symptoms begin with severe headaches and feeling of severe unwell. ...
... intake of vitamin B may be at less risk from ... of alcohol along with vitamin B may have even reduced ... happens when there is growth of abnormal or malignant cells ... was done by Swedish and American researchers, said that inadequate ...
... an injury to the knee. This may lead to inflammations ... identified a way to find out how much loss of ... in order to find out whether the injury may be ... considered to be a risk factor for arthritis, it was ...
Cached Medicine News:
... CELL-DYN are assayed linearity control kits that ... verify patient reportable range of three- and ... the linear performance of the analyzer. CVA ... ranges appropriate for each instrument model and ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release Technology essentially ... stent shortening,, Unique anatomically designed tapered ... carotid bifurcation,, 0.014 Rapid Exchange catheter ... and flexible atraumatic tip,, Radiopaque marker ...
... Para 5X is a whole blood hematology ... 60C+, 80 and 120, and the Coulter ... offers a unique white cell differential, positioning ... algorithms on the systems. The product offers ...
Medicine Products: